Clorox AI Stock Analysis
Want to see CLX full AI Analyst Report?
Clorox (CLX) AI Stock Analysis
Clorox
(NYSE:CLX)
CLX scores 64 mainly due to improving operating results and free-cash-flow generation, tempered by a pressured balance sheet with high leverage and slightly negative equity. Technicals are supportive with positive momentum and price above key averages, while valuation is helped by a moderate P/E and a high dividend yield. Earnings-call guidance was constructive but constrained by near-term inflation and margin pressure.
Clorox Key Performance Indicators (KPIs)
Revenue by SegmentHighlights income from different business units, showing which areas drive growth and profitability, and where the company might focus future investments.
Health & Wellness and Home Care are the portfolio engines — Health & Wellness shows clear late‑cycle acceleration (the June 2026 lift aligns with the GOJO contribution and strong category share gains), while Home Care’s multi‑quarter share wins underpin durable demand. International and Lifestyle are steady but less dynamic, and the erratic 'Corporate & Other' line reflects acquisition/ERP integration noise and one‑offs. Management warns of front‑loaded >$200M inflation and elevated promotions that will pressure H1 margins, but GOJO synergies and ERP productivity should support margin recovery and stable FCF in H2/FY2027.
Clorox (CLX) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $12.93B
- Dividend Yield
- 4.67%
- Average Volume (3M)
- 3.17M
- Price to Earnings (P/E)
- 19.4
- Beta (1Y)
- 0.28
- Revenue Growth
- 6.28%
- EPS Growth
- -13.15%
- Country
- US
- Employees
- 9,200
- Sector
- Consumer Defensive
- Sector Strength
- 62
- Industry
- Household & Personal Products
Clorox Business Overview & Revenue Model
Company Description
The Clorox Company is a global manufacturer and marketer of both consumer and professional products, operating through four distinct segments: Health and Wellness, Household, Lifestyle, and International. The Health and Wellness division offers a ran...
How the Company Makes Money
Clorox makes money primarily by selling branded consumer packaged goods to retail and other distributors, generating revenue when its products are purchased for resale by mass retailers, grocery stores, club stores, drugstores, home improvement retai...
Clorox Earnings Call Summary
The call was cautiously optimistic. Clorox reported a better-than-expected start, improving consumption and market-share trends, strong cost savings, positive GOJO integration progress and a robust innovation pipeline. However, these positives are being offset in the near term by $240 million of input cost inflation, front-half gross-margin compression, modest organic sales growth excluding the ERP benefit, elevated competition, consumer value-seeking behavior and continued weakness in Cat Litter. Overall, the highlights outweigh the lowlights, but management remains focused on executing a gradual recovery.
Q1-2027 Updates
Positive Updates
Negative Updates
Company Guidance
Management expects fiscal year organic sales growth of 3.5% to 4.5%, including about 3.5 points of benefit from lapping the ERP transition, or flat to plus 1% excluding the ERP; excluding the ERP, growth is expected to be down slightly in the front half and up slightly in the back half, while category growth is expected to be flat to up 1%. Input cost inflation is expected to be about $240 million, about $40 million more than initially expected and about 2.5x higher our historical annual average rate, assuming Brent annual average price would be around $100, with inflation more pronounced in the first half than in the second half. The company expects gross margin compression on average for the full year, with the front half about 1 point, 1.5 below the average and the back half higher, while SG&A moved from 16% to 15%; the long-term objective remains historical EBIT margin of about 18% and historical gross margin of 43.5% and 44%. Cost synergies from GOJO are estimated at about $50 million, with line of sight to the entire $50 million and potentially more.
Clorox Financial Statement Overview
Summary
Operating performance is improving (TTM revenue +7.1% to $7.20B) with solid profitability (~42% gross margin, ~14.6% operating margin) and constructive, growing free cash flow ($453M, +11.9%). The major offset is balance-sheet risk: high debt ($5.59B) and slightly negative equity (-$39M), which reduces flexibility and keeps financial risk elevated.
Income Statement
72PositiveBalance Sheet
28NegativeCash Flow
64Positive| Breakdown | TTM | Jun 2026 | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 7.20B | 6.72B | 7.10B | 7.09B | 7.39B | 7.11B |
| Gross Profit | 3.02B | 2.84B | 3.21B | 3.05B | 2.91B | 2.54B |
| EBITDA | 1.31B | 1.17B | 1.39B | 723.00M | 564.00M | 937.00M |
| Net Income | 677.00M | 587.00M | 810.00M | 280.00M | 149.00M | 462.00M |
Balance Sheet | ||||||
| Total Assets | 7.83B | 7.79B | 5.56B | 5.75B | 5.95B | 6.16B |
| Cash, Cash Equivalents and Short-Term Investments | 184.00M | 143.00M | 167.00M | 202.00M | 367.00M | 183.00M |
| Total Debt | 5.59B | 5.52B | 2.88B | 2.90B | 2.92B | 3.10B |
| Total Liabilities | 7.71B | 7.54B | 5.08B | 5.26B | 5.56B | 5.43B |
| Stockholders Equity | -39.00M | 90.00M | 321.00M | 328.00M | 220.00M | 556.00M |
Cash Flow | ||||||
| Free Cash Flow | 453.00M | 405.00M | 761.00M | 483.00M | 930.00M | 535.00M |
| Operating Cash Flow | 662.00M | 612.00M | 981.00M | 695.00M | 1.16B | 786.00M |
| Investing Cash Flow | -2.30B | -2.30B | -94.00M | -175.00M | -223.00M | -229.00M |
| Financing Cash Flow | 1.66B | 1.67B | -924.00M | -655.00M | -753.00M | -689.00M |
Clorox Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CLX, the sentiment is Positive. The current price of 106.70 is above the 20-day moving average (MA) of 96.36, above the 50-day MA of 88.56, and above the 200-day MA of 96.81, indicating a bullish trend. The MACD of 6.16 indicates Negative momentum. The RSI at 72.20 is Negative, neither overbought nor oversold. The STOCH value of 87.21 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for CLX.
Clorox Risk Analysis
Clorox disclosed 35 risk factors in its most recent earnings report. Clorox reported the most risks in the "Finance & Corporate" category.
Latest Risks Added
0 New RisksClorox Peers Comparison
Overall Rating
CHD78Outperform
PG72Outperform
KMB69Neutral
CL67Neutral
UL64Neutral
CLX64Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 78Outperform | $26.55B | 34.44 | 18.21% | 1.09% | 1.70% | 2.07% | |
| 72Outperform | $398.01B | 25.43 | 29.55% | 2.52% | 3.52% | -3.74% | |
| 69Neutral | $66.37B | 10.88 | 162.62% | 4.72% | -8.38% | 67.47% | |
| 67Neutral | $79.18B | 38.71 | 1135.82% | 2.12% | 5.91% | -28.30% | |
| 64Neutral | $140.97B | 14.00 | 58.26% | 3.30% | -17.45% | 8.84% | |
| 64Neutral | $12.93B | 19.38 | -1920.57% | 4.67% | 6.28% | -13.15% | |
| Sector * | 62Neutral | $20.33B | 14.63 | -3.31% | 3.23% | 1.93% | -12.26% |
* Consumer Defensive Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| CLX | Clorox Company | 106.70 | 13.03 | 13.91% | |
| CHD | Church & Dwight Company | 112.48 | 30.95 | 37.97% | |
| CL | Colgate-palmolive Company | 99.61 | 22.98 | 29.99% | |
| KMB | Kimberly Clark | 108.15 | 10.77 | 11.06% | |
| PG | Procter & Gamble Company | 171.72 | 28.88 | 20.21% | |
| UL | Unilever plc | 65.31 | 4.30 | 7.05% |
Clorox Corporate Events
Clorox Reports Strong Fiscal First-Quarter Sales and Earnings Growth
PositiveClorox is a household, cleaning and professional-products company serving consumer and healthcare markets in the U.S. and internationally, with brands spanning cleaning, bags and wraps, cat litter, grilling, food, water filtration and natural persona...
Clorox Names Fabian Garcia as Incoming CEO and Chair
PositiveOn October 28, 2026, Clorox’s board appointed veteran consumer products executive Fabian Garcia as CEO and director, effective January 5, 2027, following a search prompted by current CEO and chair Linda Rendle’s decision to step down for health reaso...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 04, 2026
